New genetic discoveries and treatment for hepatitis C

JAMA. 2012 May 9;307(18):1921-2. doi: 10.1001/jama.2012.3516.
No abstract available

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • DNA, Viral / classification
  • DNA, Viral / drug effects
  • Genotype
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / genetics*
  • Humans
  • Interferon-alpha / therapeutic use
  • Interferons
  • Interleukins / genetics*
  • Oligopeptides / therapeutic use
  • Pharmacogenetics / trends*
  • Polyethylene Glycols / therapeutic use
  • Polymorphism, Single Nucleotide
  • Precision Medicine
  • Proline / analogs & derivatives
  • Proline / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Ribavirin / therapeutic use

Substances

  • Antiviral Agents
  • DNA, Viral
  • interferon-lambda, human
  • Interferon-alpha
  • Interleukins
  • Oligopeptides
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Interferons
  • Proline
  • peginterferon alfa-2a